Search in:

Advanced search

Expert Opinion on Investigational Drugs Volume 25, 2016 - Issue 1

Submit an article Journal homepage

334

Views

CrossRef citations to date

Altmetric

Reviews

Investigational drugs for treating anal cancer and future perspectives

Liliana BustamanteDepartment of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL33612, USA

Jessica FrakesDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL33612, USA

Sarah HoffeDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL33612, USA

Richard KimDepartment of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL33612, USACorrespondence[email protected]

Pages 51-62 | Published online: 11 Dec 2015

Cite this article
https://doi.org/10.1517/13543784.2016.1116518
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
Google Scholar
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
PubMed Web of Science ®Google Scholar
Johnson LG, Madeleine MM, Newcomer LM, et al. Anal cancer incidence and survival: the surveillance, epidemiology and end results experience, 1973–2000. Cancer. 2004;101(2):281–288.
PubMed Web of Science ®Google Scholar
Klas JV, Rothenberger DA, Wong WD, et al. Malignant tumors of the anal canal. Cancer. 1999;85(8):1686–1693.
PubMed Web of Science ®Google Scholar
Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. New Engl J Med. 2000;342(11):792–800.
PubMed Web of Science ®Google Scholar
Myerson RJ, Karnell LH, Menck HR. The National Cancer Data Base report on carcinoma of the anus. Cancer. 1997;80(4):805–815.
PubMed Web of Science ®Google Scholar
Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101(2):270–280.
PubMed Web of Science ®Google Scholar
Daling JR, Weiss NS, Hislop TG, et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. New Engl J Med. 1987;317(16):973–977.
PubMed Web of Science ®Google Scholar

• Overview of risk factors of anal cancer.

Frisch M, Glimelius B, van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. New Engl J Med. 1997;337(19):1350–1358.
PubMed Web of Science ®Google Scholar
Welton ML, Sharkey FE, Kahlenberg MS. The etiology and epidemiology of anal cancer. Surg Oncol Clin North Am. 2004;13(2):263–275.
PubMedGoogle Scholar
Palefsky JM. Anal human papillomavirus infection and anal cancer in HIV-positive individuals: an emerging problem. Aids. 1994;8(3):283–296.
PubMed Web of Science ®Google Scholar
Sillman F, Sedlis A. Anogenital papillomavirus infection and neoplasia in immunodeficient women. Obstet Gynecol Clin North Am. 1987;14(2):537–558.
PubMed Web of Science ®Google Scholar
Stier EA, Sebring MC, Mendez AE, et al. Prevalence of anal human papilloma virus infection and anal HPV-related disorders in women: a systematic review. Am J Obstet Gynecol. 2015;213(3):278–309.
Google Scholar
Boman BM, Moertel CG, O’Connell MJ, et al. Carcinoma of the anal canal, a clinical and pathologic study of 188 cases. Cancer. 1984;54(1):114–125.
PubMed Web of Science ®Google Scholar
Leichman L, Nigro N, Vaitkevicius VK, et al. Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy. Am J Med. 1985;78(2):211–215.
PubMed Web of Science ®Google Scholar
Nigro ND, Vaitkevicius V, Considine B. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum. 1974;17(3):354–356.
PubMed Web of Science ®Google Scholar
Party UACTW. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet. 1996;348(9034):1049–1054.
PubMed Web of Science ®Google Scholar
Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010;102(7):1123–1128.
PubMed Web of Science ®Google Scholar
Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15(5):2040–2049.
PubMed Web of Science ®Google Scholar
Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14(9):2527–2539.
PubMed Web of Science ®Google Scholar
Ajani J, Winter K, Gunderson L, et al. Intergroup RTOG 98-11: a phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal. ASCO Annu Meet Proc. 2006;2006:4009.
Google Scholar
Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012;30(35):4344–4351.
PubMed Web of Science ®Google Scholar

•• Recent update on RTOG 98-11.

James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2× 2 factorial trial. Lancet Oncol. 2013;14(6):516–524.
PubMed Web of Science ®Google Scholar
Peiffert D, Tournier-Rangeard L, Gérard J-P, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012;35:4837.
Google Scholar
Glynne-Jones R, Meadows H, Wan S, et al. EXTRA—a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys. 2008;72(1):119–126.
PubMed Web of Science ®Google Scholar

•• The largest trial comparing role of mitomycin versus cisplatin in anal cancer.

Deenen MJ, Dewit L, Boot H, et al. Simultaneous integrated boost–intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. Int J Radiat Oncol Biol Phys. 2013;85(5):e201–e207.
Google Scholar
Meulendijks D, Dewit L, Tomasoa N, et al. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. Br J Cancer. 2014;111(9):1726–1733.
PubMed Web of Science ®Google Scholar
Eng C, Chang G, Das P, et al. Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal. ASCO Annu Meet Proc. 2009;2009:4116.
Google Scholar
Paliga A, Onerheim R, Gologan A, et al. EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors&quest. Br J Cancer. 2012;107(11):1864–1868.
PubMed Web of Science ®Google Scholar

• The article describes the incidence of EGFR and KRAS mutations in anal cancer.

Van Damme N, Deron P, Van Roy N, et al. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer. 2010;10(1):189.
PubMed Web of Science ®Google Scholar
Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. New Engl J Med. 2008;358(11):1160–1174.
PubMed Web of Science ®Google Scholar
Olivatto L, Meton F, Bezerra M, et al. Phase I study of cetuximab (CET) in combination with 5-fluorouracil (5-FU), cisplatin (CP), and radiotherapy (RT) in patients with locally advanced squamous cell anal carcinoma (LAAC). ASCO Annu Meet Proc. 2008;2008:4609.
Google Scholar
Levy A, Azria D, Pignon J-P, et al. Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial. Radiother Oncol. 2015;114(3):415.
PubMed Web of Science ®Google Scholar
Garg M, Lee JY, Kachnic LA, et al. Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): safety and preliminary efficacy results. ASCO Annu Meet Proc. 2012;2012:4030.
Google Scholar
Mouawad F, Gros A, Rysman B, et al. The antitumor drug F14512 enhances cisplatin and ionizing radiation effects in head and neck squamous carcinoma cell lines. Oral Oncol. 2014;50(2):113–119.
PubMed Web of Science ®Google Scholar
Kotowski U, Heiduschka G, Brunner M, et al. Radiosensitization of head and neck cancer cells by the phytochemical agent sulforaphane. Strahlenther Onkol. 2011;187(9):575–580.
PubMed Web of Science ®Google Scholar
Sischy B, Doggett RS, Krall JM, et al. Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314. J Natl Cancer Inst. 1989;81(11):850–857.
PubMedGoogle Scholar
Allal A, Kurtz JM, Pipard G, et al. Chemoradiotherapy versus radiotherapy alone for anal cancer: a retrospective comparison. Int J Radiat Oncol Biol Phys. 1993;27(1):59–66.
PubMed Web of Science ®Google Scholar
Das P, Bhatia S, Eng C, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007;68(3):794–800.
PubMed Web of Science ®Google Scholar

•• Randomized trial comparing the efficacy of cisplatin-based therapy versus mitomycin-based therapy in treatment of anal canal carcinoma.

Meropol NJ, Niedzwiecki D, Shank B, et al. Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). J Clin Oncol. 2008;26(19):3229–3234.
PubMed Web of Science ®Google Scholar
Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299(16):1914–1921.
PubMed Web of Science ®Google Scholar
Horner M, Ries L, Krapcho M, et al. SEER cancer statistics review, 1975–2006. Bethesda (MD): National Cancer Institute; 2009.
Google Scholar
Tanum G, Tveit K, Karlsen K, et al. Chemotherapy and radiation therapy for anal carcinoma. Survival and late morbidity. Cancer. 1991;67(10):2462–2466.
PubMed Web of Science ®Google Scholar
Faivre C, Rougier P, Ducreux M, et al. [5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer]. Bull Cancer. 1999;86(10):861–865.
PubMed Web of Science ®Google Scholar

•• Article which established 5-FU and cisplatin as standard first line treatment for advanced anal cancer.

Eng C, Pathak P. Treatment options in metastatic squamous cell carcinoma of the anal canal. Curr Treat Options Oncol. 2008;9(4–6):400–407.
PubMed Web of Science ®Google Scholar
Hainsworth JD, Burris HA, Meluch AA, et al. Paclitaxel, carboplatin, and long‐term continuous infusion of 5‐fluorouracil in the treatment of advanced squamous and other selected carcinomas. Cancer. 2001;92(3):642–649.
PubMed Web of Science ®Google Scholar
Kim R, Byer J, Fulp WJ, et al. Carboplatin and paclitaxel treatment is effective in advanced anal cancer. Oncology. 2014;87(2):125–132.
PubMed Web of Science ®Google Scholar

• Retrospective study evaluating efficacy of carboplatin and paclitaxel in advanced anal cancer.

U.S. National Institutes of Health. International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel (InterAACT) [cited 2015 Mar 23]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02051868?term=anal+cancer&recr=Open&type=Intr&phase=12&lup_s=01%2F01%2F2014&lup_e=12%2F12%2F2015&rank=3.
Google Scholar
Grifaichi F, Padovani A, Romeo F, et al. Response of metastatic epidermoid anal cancer to single agent irinotecan: a case report. Tumori. 2000;87(1):58–59.
Web of Science ®Google Scholar
Fisher W, Herbst K, Sims J, et al. Metastatic cloacogenic carcinoma of the anus: sequential responses to adriamycin and cis-dichlorodiammineplatinum (II). Cancer Treat Rep. 1978;62(1):91–97.
PubMedGoogle Scholar
Jhawer M, Mani S, Lefkopoulou M, et al. Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and bleomycin-CCNU in patients with advanced cancer of the anal canal: an eastern cooperative oncology group study E7282. Invest New Drugs. 2006;24(5):447–454.
PubMed Web of Science ®Google Scholar
Golub DV, Civelek AC, Sharma VR. A regimen of taxol, ifosfamide, and platinum for recurrent advanced squamous cell cancer of the anal canal. Chemother Res Pract. 2011;2011.
PubMedGoogle Scholar
Saif MW, Kontny E, Syrigos KN, et al. The role of EGFR inhibitors in the treatment of metastatic anal canal carcinoma: a case series. J Oncol. 2011;2011.
PubMedGoogle Scholar
Phan LK, Hoff PM. Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Dis Colon Rectum. 2007;50(3):395–398.
PubMed Web of Science ®Google Scholar
Barmettler H, Komminoth P, Schmid M, et al. Efficacy of cetuximab in combination with FOLFIRI in a patient with KRAS wild-type metastatic anal cancer. Case Rep Oncol. 2012;5(2):428–433.
PubMedGoogle Scholar
Walker F, Abramowitz L, Benabderrahmane D, et al. Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus. Hum Pathol. 2009;40(11):1517–1527.
PubMed Web of Science ®Google Scholar
Gardini AC, Capelli L, Ulivi P, et al. KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC). PloS one. 2014;9(3).
Web of Science ®Google Scholar

• The article describes the incidence of KRAS, BRAF and PIK3CA in anal cancer.

Martin V, Zanellato E, Franzetti-Pellanda A, et al. EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer. Histol Histopathol. 2014;29(4):513–521.
PubMed Web of Science ®Google Scholar
Lukan N, Ströbel P, Willer A, et al. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology. 2009;77:293–299.
PubMed Web of Science ®Google Scholar
Schneider A, Koutsky L. Natural history and epidemiological features of genital HPV infection. IARC Sci Publ. 1991;119:25–52.
Google Scholar
Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997;102(5):3–8.
PubMedGoogle Scholar
Klencke B, Matijevic M, Urban RG, et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia A phase I study of ZYC101. Clin Cancer Res. 2002;8(5):1028–1037.
PubMed Web of Science ®Google Scholar
U.S. National Institutes of Health. T cell receptor immunotherapy targeting HPV-16 E6 for HPV-associated cancers[Internet]. [cited 2015 Sep]. Available from: https://clinicaltrials.gov/ct2/show/NCT02280811
Google Scholar
U.S. National Institutes of Health. Immunotherapy using tumor infiltrating lymphocytes for patients with metastatic human papilloma virus-associated cancers [cited 2015 Mar 23]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01585428?term=anal+cancer&recr=Open&type=Intr&phase=12&lup_s=01%2F01%2F2014&lup_e=12%2F12%2F2015&rank=6.
Google Scholar
Palefsky JM, Berry JM, Jay N, et al. A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. Aids. 2006;20(8):1151–1155.
PubMed Web of Science ®Google Scholar
U.S. National Institutes of Health. A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer (276) [cited 2015 Mar 23]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01671488?term=anal+cancer&recr=Open&type=Intr&phase=12&lup_s=01%2F01%2F2014&lup_e=12%2F12%2F2015&rank=1.
Google Scholar
Petit RG, Basu P. ADXS11-001 immunotherapy targeting HPV-E7: updated survival and safety data from a phase 2 study in Indian women with recurrent/refractory cervical cancer. J Immunother Cancer. 2013;1(1):1.
PubMedGoogle Scholar
Mayes G. Advaxis presents preliminary data from a phase 1/2 trial of ADXS-HPV in HPV-associated anal cancer in combination with chemoradiation showing complete response and no recurrences to date in all treated patients. Paper presented at International Anal Neoplasia Society (IANS) Scientific Meeting; 2015 Mar 13–15; Atlanta, GA.
Google Scholar
Stevanović S, Draper LM, Langhan MM, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus–targeted tumor-infiltrating T cells. J Clin Oncol. 2015;58:9093.
Google Scholar
Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867.
PubMed Web of Science ®Google Scholar
Hald J, Rasmussen N, Claesson MH. In vivo infiltration of mononuclear cells in squamous cell carcinoma of the head and neck correlated with the ability to expand tumour-infiltrating T cells in vitro and with the expression of MHC class I antigens on tumour cells. Cancer Immunol Immunother. 1994;39(6):383–390.
PubMed Web of Science ®Google Scholar
Bradburn JE, Pei P, Kresty LA, et al. The effects of reactive species on the tumorigenic phenotype of human head and neck squamous cell carcinoma (HNSCC) cells. Anticancer Res. 2007;27(6B):3819–3827.
PubMed Web of Science ®Google Scholar
Belai EB, de Oliveira CE, Gasparoto TH, et al. PD-1 blockage delays murine squamous cell carcinoma development. Carcinogenesis. 2014;35(2):424–431.
PubMed Web of Science ®Google Scholar
U.S Food and Drug Administration. FDA expands approved use of opdivo to treat lung cancer [cited 2015 Mar 23]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436534.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery.
Google Scholar
Administration USFaD. FDA approves Keytruda for advanced non-small cell lung cancer. 2015 [cited 2015 Oct 9]; Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm465444.htm.
Google Scholar
Stier EA, Goldstone SE, Einstein MH, et al. Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women. AIDS. 2013;27(4):545.
PubMed Web of Science ®Google Scholar
Dasgupta T, Rothenstein D, Chou JF, et al. Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis. Radiother Oncol. 2013;107(2):189–194.
PubMed Web of Science ®Google Scholar
Chuong MD, Freilich JM, Hoffe SE, et al. Intensity-modulated radiation therapy vs. 3D conformal radiation therapy for squamous cell carcinoma of the anal canal. Gastrointest Cancer Res. 2013;6(2):39–45.
PubMedGoogle Scholar
Bazan JG, Hara W, Hsu A, et al. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer. 2011;117(15):3342–3351.
PubMed Web of Science ®Google Scholar

• Compares IMRT versus standard radiation therapy in anal cancer.

Dewas CV, Maingon P, Dalban C, et al. Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer? Radiat Oncol. 2012;7:201.
PubMed Web of Science ®Google Scholar
Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86(1):27–33.
PubMed Web of Science ®Google Scholar
Peto J, Gilham C, Fletcher O, et al. The cervical cancer epidemic that screening has prevented in the UK. Lancet. 2004;364(9430):249–256.
PubMed Web of Science ®Google Scholar
Van Kriekinge G, Castellsagué X, Cibula D, et al. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths. Vaccine. 2014;32(6):733–739.
PubMed Web of Science ®Google Scholar
Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. New Engl J Med. 2011;365(17):1576–1585.
PubMed Web of Science ®Google Scholar

•• Large double-blind study demonstrating HPV vaccine reducing the rate of anal intraepithelial neoplasia.

Chiao EY, Giordano TP, Palefsky JM, et al. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis. 2006;43(2):223–233.
PubMed Web of Science ®Google Scholar
Lampejo T, Kavanagh D, Clark J, et al. Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review. Br J Cancer. 2010;103(12):1858–1869.
PubMed Web of Science ®Google Scholar
Eschrich SA, Pramana J, Zhang H, et al. A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys. 2009;75(2):489–496.
PubMed Web of Science ®Google Scholar
Ahmed KA, Fulp WJ, Berglund AE, et al. Differences between colon cancer primaries and metastases using a molecular assay for tumor radiation sensitivity suggest implications for potential oligometastatic SBRT patient selection. Int J Radiat Oncol Biol Phys. 2015;92(4):837–842.
Web of Science ®Google Scholar
Eschrich SA, Fulp WJ, Pawitan Y, et al. Validation of a radiosensitivity molecular signature in breast cancer. Clin Cancer Res. 2012;18(18):5134–5143.
PubMed Web of Science ®Google Scholar
Evans T, Mansi J, Glees J. Response of metastatic anal carcinoma to single agent carboplatin. Clin Oncol. 1993;5(1):57–58.
Google Scholar
Wilking N, Petrelli N, Herrera L, et al. Phase II study of combination bleomycin, vincristine and high-dose methotrexate (bom) with leucovorin rescue in advanced squamous cell carcinoma of the anal canal. Cancer Chemother Pharmacol. 1985;15(3):300–302.
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Investigational drugs for treating anal cancer and future perspectives

Bibliography

• Overview of risk factors of anal cancer.

•• Recent update on RTOG 98-11.

•• The largest trial comparing role of mitomycin versus cisplatin in anal cancer.

• The article describes the incidence of EGFR and KRAS mutations in anal cancer.

•• Randomized trial comparing the efficacy of cisplatin-based therapy versus mitomycin-based therapy in treatment of anal canal carcinoma.

•• Article which established 5-FU and cisplatin as standard first line treatment for advanced anal cancer.

• Retrospective study evaluating efficacy of carboplatin and paclitaxel in advanced anal cancer.

• The article describes the incidence of KRAS, BRAF and PIK3CA in anal cancer.

• Compares IMRT versus standard radiation therapy in anal cancer.

•• Large double-blind study demonstrating HPV vaccine reducing the rate of anal intraepithelial neoplasia.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Investigational drugs for treating anal cancer and future perspectives

Bibliography

• Overview of risk factors of anal cancer.

•• Recent update on RTOG 98-11.

•• The largest trial comparing role of mitomycin versus cisplatin in anal cancer.

• The article describes the incidence of EGFR and KRAS mutations in anal cancer.

•• Randomized trial comparing the efficacy of cisplatin-based therapy versus mitomycin-based therapy in treatment of anal canal carcinoma.

•• Article which established 5-FU and cisplatin as standard first line treatment for advanced anal cancer.

• Retrospective study evaluating efficacy of carboplatin and paclitaxel in advanced anal cancer.

• The article describes the incidence of KRAS, BRAF and PIK3CA in anal cancer.

• Compares IMRT versus standard radiation therapy in anal cancer.

•• Large double-blind study demonstrating HPV vaccine reducing the rate of anal intraepithelial neoplasia.

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date